Kiromic BioPharma (DB:5JU0) - Aktienkurs, Nachrichten und Analyse

5JU0 Aktienübersicht

A clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors.

Über das Unternehmen

5JU0 grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	0/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	2/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Die Erträge sind in den letzten 5 Jahren um 40.5% pro Jahr zurückgegangen

Hat keine nennenswerte Marktkapitalisierung (€3M)

Erzielt weniger als 1 Million USD an Einnahmen ($0)

Negatives Eigenkapital

+ 2 mehr Risiken

Kiromic BioPharma, Inc. Wettbewerber

bioXXmed

XTRA:T5O

€2.4m

Atreca

DB:0C1

€1.7m

co.don

XTRA:CNW

€6.5m

Deutsche Biotech Innovativ

MUN:DBI

€1.1m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Kiromic BioPharma
Historische Aktienkurse
Aktueller Aktienkurs	US$4.10
52-Wochen-Hoch	US$18.45
52-Wochen-Tief	US$3.65
Beta	0.18
11 Monat Veränderung	0%
3 Monate Veränderung	-10.10%
1 Jahr Veränderung	-72.67%
33 Jahre Veränderung	n/a
5 Jahre Veränderung	n/a
Veränderung seit IPO	-98.14%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	5JU0	DE Biotechs	DE Markt
7D	0%	4.4%	0.9%
1Y	-72.7%	-16.6%	3.0%

Rendite im Vergleich zur Industrie: 5JU0 unter dem Niveau der Branche German Biotechs, die im vergangenen Jahr eine Rendite von -24.7% erzielte.

Rendite vs. Markt: 5JU0 hinter dem Markt German zurück, der im vergangenen Jahr eine Rendite von 5.2 erzielte.

Preisvolatilität

Is 5JU0's price volatile compared to industry and market?
5JU0 volatility
5JU0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.4%
10% least volatile stocks in DE Market	2.5%

Stabiler Aktienkurs: 5JU0 hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von 5JU0 im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2006	31	Pietro Bersani	kiromic.com

Kiromic BioPharma, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Kiromic BioPharma im Vergleich zum Marktanteil des Unternehmens?
5JU0 grundlegende Statistiken
Marktanteil	€2.77m
Gewinn(TTM)	-€30.72m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

-0.1x

Kurs-Gewinn-Verhältnis

Ist 5JU0 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
5JU0 Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$0
Kosten der Einnahmen	US$0
Bruttogewinn	US$0
Sonstige Ausgaben	US$33.01m
Umsatz	-US$33.01m

Zuletzt gemeldete Gewinne

Mar 31, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-33.71
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	-122.6%

Wie hat sich 5JU0 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

5JU0 Aktienübersicht

Belohnungen

Risikoanalyse

Kiromic BioPharma, Inc. Wettbewerber

XTRA:T5O

€2.4m

DB:0C1

€1.7m

XTRA:CNW

€6.5m

MUN:DBI

€1.1m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Kiromic BioPharma, Inc. Provides Updates on Its Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients

Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial

Recent updates

Kiromic BioPharma, Inc. Provides Updates on Its Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients

Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months

Kiromic Biopharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer

Kiromic Biopharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial

Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer

Nasdaq to Delist the Securities of Kiromic BioPharma

Kiromic Biopharma, Inc. Announces Deltacel™? Phase 1 Clinical Trial Enters Patient Recruitment Phase At Beverly Hills Cancer Center

Kiromic BioPharma, Inc.(OTCPK:KRBP) dropped from NASDAQ Composite Index

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14, 2023, Suspended from Trading on Nasdaq Capital Market

Kiromic Biopharma, Inc. Announces Board Appointments

Kiromic BioPharma, Inc. announced that it has received $2.4 million in funding

Kiromic BioPharma, Inc., Annual General Meeting, Jul 25, 2023

Kiromic Biopharma, Inc Appoints Brian Hungerford as Interim Chief Financial Officer

Kiromic BioPharma, Inc. Announces the Resignation of Dan Clark as Chief Financial Officer

Kiromic Biopharma, Inc. Announces Resignation of Karen Reeves as Director

Kiromic BioPharma Receives Non-Compliance Notice from Nasdaq

Frank Tirelli Resigns His Position as Director and Member of the Audit Committee, and the Nominating and Corporate Governance Committee of Kiromic Biopharma, Inc

High number of new and inexperienced directors

Kiromic BioPharma, Inc. announced that it has received $2 million in funding

Kiromic Biopharma Announces FDA Feedback from Type B Pre-Ind Meeting Confirms Deltacel Development Strategy

Gainey Mckenna & Egleston Files the First Class Action Lawsuit Against Kiromic Biopharma, Inc

Nasdaq Grants Extension to Kiromic BioPharma to Regain Compliance

The Klein Law Firm Announces Class Action Complaint Against Kiromic Biopharma, Inc

Gainey McKenna & Egleston Files Class Action Lawsuit Against Kiromic BioPharma, Inc

Kiromic BioPharma, Inc. Appoints Leonardo Mirandola as Chief Scientific Officer

High number of new and inexperienced directors

Kiromic BioPharma, Inc. Appoints Pietro Bersani to the Role of Chief Executive Officer, Effective May 10, 2022

Kiromic BioPharma, Inc. Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022

Kiromic BioPharma, Inc., Annual General Meeting, Jun 22, 2022

Kiromic BioPharma, Inc. announced delayed annual 10-K filing

Kiromic BioPharma, Inc. Announces Board Appointments

High number of new and inexperienced directors

Kiromic BioPharma Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

High number of new and inexperienced directors

Kiromic BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy

Kiromic Biopharma, Inc. Announces Identification of Novel Targets for Allogeneic Car Gamma Delta T-Cell Therapy in Solid Tumors Utilizing Kiromic’s Proprietary Artificial Intelligence Engine

Kiromic BioPharma, Inc. Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor - Gamma Delta T-cell Therapy

Kiromic Biopharma, Inc. to Resubmit Two Expanded INDs to the FDA for its Allogenic, Off-the-Shelf Gamma-Delta T cell Therapies for Multiple Solid Tumors

Kiromic Biopharma, Inc. Enters into A Strategic Alliance Agreement with Leon Office (H.K.) Ltd

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Kiromic BioPharma, Inc.'s Grundlagenzusammenfassung

0.0x

-0.1x

Erträge &amp; Einnahmen

Erträge & Einnahmen